Last reviewed · How we verify
Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab
Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab is a Small molecule drug developed by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano. It is currently in Phase 2 development. Also known as: FOLFOX-4 + panitumumab.
At a glance
| Generic name | Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab |
|---|---|
| Also known as | FOLFOX-4 + panitumumab |
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial (PHASE2)
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (PHASE2)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- Botensilimab and Balstilimab Optimization in Colorectal Cancer (PHASE2)
- Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver (PHASE2)
- An Additional Analysis of Data From the PARADIGM Exploratory Study (NCT02394834) in Patients With Advanced/Recurrent Colorectal Cancer
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (PHASE1)
- A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab CI brief — competitive landscape report
- Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab updates RSS · CI watch RSS
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano portfolio CI
Frequently asked questions about Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab
What is Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab?
Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab is a Small molecule drug developed by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
Who makes Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab?
Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab is developed by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (see full Fondazione IRCCS Istituto Nazionale dei Tumori, Milano pipeline at /company/fondazione-irccs-istituto-nazionale-dei-tumori-milano).
Is Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab also known as anything else?
Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab is also known as FOLFOX-4 + panitumumab.
What development phase is Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab in?
Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab is in Phase 2.
Related
- Manufacturer: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano — full pipeline
- Also known as: FOLFOX-4 + panitumumab
- Compare: Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab vs similar drugs
- Pricing: Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab cost, discount & access